Archives
Metabolic Acidosis In Chronic Kidney Disease (CKD)
Thank you for attending, we hope you enjoyed this webinar.
Please tell us what you thought about today’s presentation by taking the survey below:
About This Event
Metabolic Acidosis In Chronic Kidney Disease (CKD)
Background
Metabolic acidosis in chronic kidney disease (CKD), defined as total CO2 <22 mEq/L, is one of the earliest complications of CKD and has been identified as risk factor for CKD progression, renal replacement therapy, mortality.1,2,3 While metabolic acidosis can be present all different stages of CKD, it is most common in patients with eGFR <40 mL/min/1.73 m2.1 Some studies suggest that correcting metabolic acidosis with alkali therapy may slow down CKD progression.1,4Did You Know?
- In non-dialysis CKD 3-5 patients with metabolic acidosis, a 1mEq/L increase in serum bicarbonate was associated with a 13% reduction in a 2-year composite DD40 (death, dialysis, or 40% reduction in eGFR), and a 7% reduction in per-patient per-year cost?5
- Expert nephrologist, Dr. Samuel A Kantor, will discuss metabolic acidosis in CKD.
- The relationship between metabolic acidosis and hyperkalemia in chronic kidney disease (CKD)
- The role of metabolic acidosis in CKD progression and other complications
- The role of alkali replacement in metabolic acidosis treatment
- Raphael Kl. Am J Kidney Dis. 2019;74(2):263-275.
- Wesson DE, Buysse JM, Bushinsky DA. J Am Soc Nephrol. 2020 ;31 :469-482.
- Tangri N, et al. BMC Nephrology. 2021;22(185):1-11.
- Navaneethan SD, Shao J, Buysse J, et al. Clin J Am Soc Nephrol. 2019 ;14(7) :1011-1020. DOI : 10.2215/CJN.13091118.
- Reaven NL, Funk SE, Mathur V, et al. Kidney Med. 2023;5(5):1-8.
Featuring
Samuel Kantor, MD
Nevada Kidney Disease and Hypertension Centers*
Dr Kantor received his postgraduate training at Medical College of Pennsylvania and Hahnemann University College of Medicine in Philadelphia, PA. Dr Kantor did his fellowship training at Drexel University College of Medicine in Philadelphia, PA and was Chief Nephrology Fellow. He is a partner at Nevada Kidney Disease and Hypertension Centers in Las Vegas, NV and is a principal investigator and sub-investigator in multiple phase 2 and 3 clinical studies undertaken by the practice. Dr Kantor has been board-certified in Nephrology since 2003. He was awarded ‘Top Doctor’ Status by Las Vegas INC. Magazine in their healthcare issue in 2015, 2016, and 2023. He was also awarded ‘Top Doctor’ status by Desert Companion Magazine in 2021 and 2022.
Moderating
Rim Hadgu, PharmD, BCPS
Otsuka Pharmaceutical Development & Commercialization, Inc.*
Dr Rim Hadgu is a Nephrology Medical Science Liaison at Otsuka Pharmaceutical Development and Commercialization. She obtained her Doctor of Pharmacy degree from St. Louis College of Pharmacy. She completed an American Society of Health-System Pharmacists (ASHP)-Accredited PGY1 Pharmacy Residency at Xavier University of Louisiana College of Pharmacy and University Medical Center New Orleans. She also completed an ASHP-Accredited PGY2 Nephrology Pharmacy Residency at Albany College of Pharmacy and Health Sciences. Prior to joining Otsuka in October 2021, she was an Assistant Professor of Pharmacy Practice at Midwestern University College of Pharmacy, Glendale Campus where she delivered lectures, precepted Advanced Pharmacy Practice Experience students as well as PGY1 and PGY2 pharmacy residents. She also practiced as a nephrology clinical pharmacist for two years. Dr Hadgu is a Board Certified Pharmacotherapy Specialist by the Board of Pharmacy Specialties.
*Dr Samuel Kantor is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC). Dr Rim Hadgu is an employee of OPDC.
